RUNX1/CD44 axis regulates the proliferation, migration, and immunotherapy of gliomas: A single-cell sequencing analysis

Hao Zhang; Hui Cao; Hui Cao; Hong Luo; Nan Zhang; Zeyu Wang; Zeyu Wang; Ziyu Dai; Ziyu Dai; Wantao Wu; Wantao Wu; Guodong Liu; Zongyi Xie; Quan Cheng; Quan Cheng; Yuan Cheng

doi:10.3389/fimmu.2023.1086280

Frontiers in Immunology (Jan 2023)

RUNX1/CD44 axis regulates the proliferation, migration, and immunotherapy of gliomas: A single-cell sequencing analysis

Hao Zhang,
Hui Cao,
Hui Cao,
Hong Luo,
Nan Zhang,
Zeyu Wang,
Zeyu Wang,
Ziyu Dai,
Ziyu Dai,
Wantao Wu,
Wantao Wu,
Guodong Liu,
Zongyi Xie,
Quan Cheng,
Quan Cheng,
Yuan Cheng

Affiliations

Hao Zhang: Department of Neurosurgery, The Second Affiliated Hospital, Chongqing Medical University, Chongqing, China
Hui Cao: Department of Psychiatry, Brain Hospital of Hunan Province, The Second People’s Hospital of Hunan Province, Changsha, China
Hui Cao: The School of Clinical Medicine, Hunan University of Chinese Medicine, Changsha, China
Hong Luo: Department of Neurosurgery, The Second Affiliated Hospital, Chongqing Medical University, Chongqing, China
Nan Zhang: College of Life Science and Technology, Huazhong University of Science and Technology, Wuhan, China
Zeyu Wang: Department of Neurosurgery, Xiangya Hospital, Central South University, Changsha, China
Zeyu Wang: National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, China
Ziyu Dai: Department of Neurosurgery, Xiangya Hospital, Central South University, Changsha, China
Ziyu Dai: National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, China
Wantao Wu: National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, China
Wantao Wu: Department of Oncology, Xiangya Hospital, Central South University, Changsha, China
Guodong Liu: Department of Neurosurgery, The Second Affiliated Hospital, Chongqing Medical University, Chongqing, China
Zongyi Xie: Department of Neurosurgery, The Second Affiliated Hospital, Chongqing Medical University, Chongqing, China
Quan Cheng: Department of Neurosurgery, Xiangya Hospital, Central South University, Changsha, China
Quan Cheng: National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, China
Yuan Cheng: Department of Neurosurgery, The Second Affiliated Hospital, Chongqing Medical University, Chongqing, China

DOI: https://doi.org/10.3389/fimmu.2023.1086280
Journal volume & issue: Vol. 14

Abstract

Read online

BackgroundGlioma is one of the most common, primary, and lethal adult brain tumors because of its extreme aggressiveness and poor prognosis. Several recent studies relevant to the immune function of CD44, a transmembrane glycoprotein as a significant hyaluronic acid receptor, have achieved great success, revealing the critical role of CD44 in immune infiltration in gliomas. The overexpression of CD44 has been verified to correlate with cancer aggressiveness and migration, while the clinical and immune features of CD44 expression have not yet been thoroughly characterized in gliomas.MethodsMolecular and clinical data of glioma collected from publicly available genomic databases were analyzed.ResultsCD44 was up-expressed in malignant gliomas, notably in the 1p/19q non-codeletion cases, isocitrate dehydrogenase (IDH) wild-type, and mesenchymal subtypes in GBM samples. CD44 expression level strongly correlates with stromal and immune cells, mainly infiltrating the glioma microenvironment by single-cell sequencing analysis. Meanwhile, CD44 can be a promising biomarker in predicting immunotherapy responses and mediating the expression of PD-L1. Finally, RUNX1/CD44 axis could promote the proliferation and migration of gliomas.ConclusionsTherefore, CD44 was responsible for glioma growth and progression. It could potentially lead to a novel target for glioma immunotherapy or a prognostic biomarker.

Published in Frontiers in Immunology

ISSN: 1664-3224 (Online)
Publisher: Frontiers Media S.A.
Country of publisher: Switzerland
LCC subjects: Medicine: Internal medicine: Specialties of internal medicine: Immunologic diseases. Allergy
Website: http://journal.frontiersin.org/journal/immunology

About the journal

Abstract

Keywords